Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-ErbB2 antibody drug conjugate, Anti-HER2 antibody drug conjugate, BAT 8001 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Phase 3 | China | 25 Aug 2018 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | China | 01 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 21 Jun 2019 | |
HER2 Positive Solid Tumors | Phase 2 | China | 08 Apr 2019 |
Phase 3 | HER2 Positive Breast Cancer HER2 阳性 | - | bfzyfxugue(shlgnupkjn) = 与阳性对照组拉帕替尼联合卡培他滨比较未达到预设的优效目标 yfclyaqgzx (sgrcupezvx ) Not Met | Negative | 09 Feb 2021 | ||
Phase 1 | HER2 Positive Breast Cancer HER2-positive | 29 | tueygkkztm(hzylteiarh) = occurred in 14 (48.3%) of 29 patients, including thrombocytopenia in 12 (41.4%) patients, aspartate aminotransferase increased in 4 (13.8%) patients, γ-glutamyl transferase increased in 2 (6.9%) patients, alanine aminotransferase increased in 2 (6.9%) patients, diarrhea in 2 (6.9%) patients cwftdlbskt (cuxfbimkeu ) View more | Positive | 01 Feb 2021 | ||
Not Applicable | HER2 Positive Breast Cancer HER2-positive | - | odygzkhvlw(dxhhonhrxo) = aibfhjwpnn aqixfaufct (wyfkagfvck ) View more | - | 15 Feb 2019 | ||
myyedloshr(akswmugove) = yycamlrkpx fwannujxjd (hslifcoupm ) |